Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies

Webinars

Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies

January 26, 2022

Speakers:

Abie Ekangi, Ph.D.

Vice President. Statistical Consulting

Andreas Schreiner, MD

Vice President, Medical Affairs Neuroscience & Analgesia

Ready to get started? So are we.

Drop us a line to learn more about how we can help.